Amgen stock after-hours at EUR 356.18: minus 0.79 percent versus Lang & Schwarz prior close
Published on 10/06/2026 at 20:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock was at EUR 356.18 after-hours at 8:01 p.m. CEST on October 6, 2026, down 0.79 percent versus the Lang & Schwarz prior close of October 5, 2026. Lang & Schwarz showed a bid of EUR 356.15 and an ask of EUR 356.20.
After-hours trading on October 6, 2026
The latest price was EUR 2.85 below the previous close of EUR 359.03 at Lang & Schwarz. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Amgen stock.
Amgen named among Arboretum investors
Business Wire reported on October 6 that Arboretum LifeSciences launched with $30 million in Series A financing led by F-Prime, GV, .406 Ventures, Hims & Hers, Amgen and other investors. The Cambridge, Massachusetts-based company is developing an AI and genetic-testing platform intended to support precision medicine and genomically stratified clinical research. Michael Montalto, Amgen's vice president of Precision Medicine, said the platform could help expand access to molecular and clinical datasets for drug development.
Earlier pipeline update
In a September 22 release, Amgen said its Phase 3 OASIZ 301 study of dazodalibep in adults with moderate-to-severe systemic Sjögren's disease met its primary endpoint. The company reported statistically significant and clinically meaningful improvement in systemic disease activity at Week 48, measured by the EULAR Sjögren's Syndrome Disease Activity Index.
